<DOC>
	<DOC>NCT01720056</DOC>
	<brief_summary>Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard treatment is yet to be clarified. This randomized clinical pilot study will compare the effects of two local treatments for preventing keloid recurrence after surgical removal; steroid and verapamil. Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.</brief_summary>
	<brief_title>Verapamil vs Steroid to Prevent Keloid Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Keloid</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Patient undergoing surgical removal of keloid Patient 18 years old or greater Length of excisional scar after surgical removal of keloid between 2 and 10 cm Keloid in face or hands Pregnancy or lactation Dementia Any heart or pulmonary condition Systemic treatment with betablockers, ACEinhibitors or calcium antagonists Systemic corticosteroidal therapy Intralesional steroid treatment within 2 months of surgery to remove keloid Flap surgery Lesions to face, hands and other cosmetically sensitive areas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>